CDNA Q4 Financial Results: Analyzing CareDx's Revenue Growth and Market Position

CareDx (CDNA) wrapped up 2025 on a mixed note, delivering a fourth-quarter performance that exceeded revenue expectations while falling short on earnings. For the period ended December 2025, the company posted revenues of $108.39 million, reflecting robust top-line momentum with a 25.2% year-over-year increase. However, earnings per share (EPS) declined to $0.12 from $0.18 in the prior-year quarter, signaling margin pressure despite strong sales growth.

The revenue beat impressed Wall Street by 5.66% above the Zacks Consensus Estimate of $102.58 million. Yet the EPS disappointment was more pronounced, coming in 48.94% below the consensus forecast of $0.24. This divergence between revenue strength and earnings weakness reveals important dynamics about CDNA’s operational efficiency and cost structure entering 2026.

Dissecting CDNA’s Revenue Streams: Where Growth is Happening

The strength of CareDx’s top line becomes clearer when examining its three primary revenue channels, each showing distinct momentum patterns.

The Patient and Digital Solutions segment generated $16.76 million, surpassing the two-analyst consensus of $15.25 million. This segment demonstrates the most impressive growth trajectory, with a 47.1% year-over-year surge. This acceleration suggests CareDx is successfully penetrating digital healthcare channels and expanding its patient engagement capabilities.

Testing Services, the company’s largest revenue pillar, delivered $78.37 million against an expected $74.95 million. While this beat analyst estimates by $3.4 million, the 22.8% year-over-year growth rate—though solid—was slower than the company’s digital segment expansion. This segment remains the revenue foundation for CDNA, comprising roughly 72% of total quarterly revenue.

The Product segment contributed $13.26 million, marginally ahead of the $12.45 million estimate. At 16.6% year-over-year growth, this division is expanding but at a more moderate pace relative to digital solutions. This three-part revenue structure shows CareDx is successfully diversifying its income sources while maintaining core testing service momentum.

Market Reception and Forward Outlook

CDNA shares have faced headwinds recently, declining 9.7% over the past month compared to a 1% dip in the broader S&P 500 composite. The market’s muted reaction to the revenue beat, combined with the EPS miss, suggests investors are closely scrutinizing the company’s profitability trajectory.

Currently holding a Zacks Rank of #3 (Hold), CareDx is positioned to move in line with market expectations for the near term. This neutral stance reflects the tension between impressive revenue growth and disappointing bottom-line results—a pattern investors will want to monitor as 2026 unfolds. The company’s ability to convert revenue gains into earnings improvements will be critical to restoring investor confidence and driving stock performance.